All articles tagged with #barretts esophagus
A Cambridge-led study provides strong evidence that Barrett’s esophagus is the universal precursor to esophageal adenocarcinoma, even when visible signs are absent at diagnosis, by showing nearly identical DNA mutations across cancers. Researchers also identified biomarkers like TFF3 and REG4 that persist through disease, suggesting molecular screening could detect hidden pre-cancer risk and enable earlier intervention.
A retired individual with Barrett's esophagus and concerns about the effects of proton-pump inhibitors (PPIs) on dementia and neuropathy seeks advice from Dr. Keith Roach. While studies on the link between PPIs and atrial fibrillation (AFib) are inconclusive, the risk of esophageal cancer due to untreated acid reflux in Barrett's esophagus patients is a key concern. Dr. Roach recommends PPIs over H2 blockers for reducing the risk of esophageal cancer, despite known risks such as potential B12 deficiency and neuropathy. He emphasizes the importance of routine endoscopic surveillance and biopsies for early detection and treatment of any abnormal esophageal growth.